NCT04276870View on ClinicalTrials.gov

Orphan Indications for CD19 Redirected Autologous T Cells

PHASE2RecruitingINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

March 12, 2020

Primary Completion Date

March 10, 2028

Study Completion Date

March 10, 2037

Conditions
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Interventions
BIOLOGICAL

Murine CART19

CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

lead

Stephan Grupp MD PhD

OTHER